Your session is about to expire
← Back to Search
PLX038 + Rucaparib for Solid Cancers and Small Cell Lung Cancer
Study Summary
This trial is testing a combination of two drugs to see if it can safely shrink tumors in people with solid tumors, SCLC, or small cell cancer outside their lungs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Gilbert's syndrome.I have a confirmed diagnosis of a solid tumor, small cell lung cancer, or small cell cancer outside the lungs.I do not have any severe illnesses or social situations that could affect my treatment.I haven't had cancer treatment or major surgery in the last 2 weeks.I can take care of myself and perform daily activities.My liver is functioning within the required levels for the trial.My kidney function is within the required range.I have brain metastases but no symptoms, or they have been treated.You have enough healthy blood cells, including white blood cells, neutrophils, and platelets, and a minimum level of hemoglobin.I am not on antiviral drugs for HIV, HCV, or HBV.Participants must have a measurable disease according to a specific set of guidelines.I am not pregnant or breastfeeding.I have a specific genetic variant that affects my drug processing.I have not had radiotherapy in the last 24 hours.I have had allergic reactions to drugs similar to PLX038 or rucaparib.My cancer has worsened after initial chemotherapy and I have no other treatment options.I am not taking strong medication that affects liver enzymes during the trial.I am 18 years old or older.My condition cannot be cured with surgery.
- Group 1: Phase IIA Arm 2
- Group 2: Phase I Arm 1 Level 1, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 400 mg
- Group 3: Phase IIB Arm 2
- Group 4: Phase I - Arm 1 Level 1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 300 mg
- Group 5: Phase I Arm 1 Level -1A, PLX038 (PEGylated SN38) 1.3 g/m^2 and Rucaparib 200 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To the best of your knowledge, are there any other similar ongoing studies?
"PLX038 has been under clinical study since 2014. The first trial, sponsored by Clovis Oncology, Inc., was completed that year with 564 participants. Based on the success of the initial Phase 3 drug trial, PLX038 received approval and is now being studied in 35 active trials involving 861 cities and 34 countries."
How many test subjects are included in this experiment?
"That is correct. The information available on clinicaltrials.gov indicates that this study is still recruiting patients. This trial was first posted on April 8th, 2020 and was last edited on November 16th, 2020. So far, 65 patients have been admitted at 1 site."
Are we still enrolling people for this experiment?
"Yes, as per the clinicaltrials.gov website, this study is still looking for willing participants. The trial was initially posted on April 8th 2020 with the latest update being from November 16th 2022."
What goals does this clinical trial hope to accomplish?
"The primary metric that will be used to determine success in this clinical trial is MTD during Phase I, with secondary measures including Toxicities, Overall Survival, and Clinical Response Rate."
Share this study with friends
Copy Link
Messenger